Post-ASH 2022 iwAL – Acute Myeloid Leukemia (AML) Highlights

Free-to-attend Virtual Workshop by VJHemOnc featuring presentations & discussions
on selected AML abstracts from the 64^th ASH Annual Meeting

Wednesday 11 January | 10:00 – 14:00 EST/ 15:00 – 19:00 GMT/ 16:00 – 20:00 CET

This event is for hematologists, researchers, nurses, and allied medical professionals only.
We will review your application and confirm your registration on submission.
By applying, you confirm that VJHemOnc can communicate with you regarding this event and share relevant hematology news.

Chairs:

Naval Daver, Houston, USA
Marina Konopleva, Houston, USA
Charles Craddock, Birmingham, UK
Andrew Wei, Melbourne, Australia

Agenda (All times EST)

Session 1: Venetoclax regimens/combinations
10:00 – 10:55 

Chair/Moderator: Marina Konopleva 

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
Naval Daver (61)

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features
Sameem Abedin (65)

Long-Term Follow-up of the Phase 3 VIALE-A Clinical Trial of Venetoclax Plus Azacitidine or Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
Courtney DiNardo (219)

Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia
Stephane de Botton (222)

ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine
Daniel Pollyea (602)

Panel discussion
10:35 – 10:55         

Session 2: Novel targeted or immune therapies
10:55 – 11:30

Chair/Moderator: Andrew Wei and Courtney DiNardo

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
Ing Tiong (606)

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Tapan Kadia (709)

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
Giovanni Marconi (701)

Panel Discussion
11:10 – 11:30

Session 3: Novel therapies
11:30 – 12:05

Chair/Moderator: Naval Daver and Kendra Sweet

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Kendra Sweet (62)

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study
Ghayas Issa (63)

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Harry Erba  (64)

Panel discussion
11:45 – 12:05                

Session 4: FLT3
12:05 – 12:40

Chair/Moderator: Naval Daver and Mark Levis

Quantum-First Trial: FLT3-ITD–Specific MRD Clearance Is Associated with Improved Overall Survival
Mark Levis (225)

High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
Chyn Chua (1456)

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
Nicholas Short (801)

Panel discussion
12:20 – 12:40            

Session 5: Chemotherapy/targeted therapies
12:40 – 13:10    

Chair/Moderator: Andrew Wei and Marina Konopleva

Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial
Jad Othman (431) 

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
Felicitas Thol (832) 

Panel discussion
12:50 – 13:10

Session 6: Immunotherapies/SCT
13:10 – 14:05

Chair/Moderator: Charles Craddock and Naval Daver

In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial
Johannes Schetelig (4)

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703 
Shernan Holtan (LBA-4)

Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
Amandeep Salhotra (779)

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3–Internal Tandem Duplication: Results from the Quantum-First Trial
Alexander Perl (878)

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)
David Sallman (981)

Target Densities in Malignant and Normal Cells Determine CAR T Cell Efficacy and Off-Target Hematotoxicity
Sascha Haubner (358)

The Race Is on: BiTE Vs CAR-T As FLT3-Directed Immunotherapies in AML
Marion Subklewe (4595) 

Panel discussion
13:40 – 13:45

END OF WORKSHOP
13:45

This event is for hematologists, researchers, nurses, and allied medical professionals only.
We will review your application and confirm your registration on submission.
By applying, you confirm that VJHemOnc can communicate with you regarding this event and share relevant hematology news.